Last reviewed · How we verify
SARS-CoV-2 convalescent plasma treatment
SARS-CoV-2 convalescent plasma treatment is a Biologic drug developed by Fundación Santa Fe de Bogota. It is currently in Phase 2 development.
At a glance
| Generic name | SARS-CoV-2 convalescent plasma treatment |
|---|---|
| Sponsor | Fundación Santa Fe de Bogota |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Testing Convalescent Plasma vs Best Supportive Care (PHASE1)
- Intermediate IND Severe Illness COVID-19 CP (PHASE1)
- Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma (NA)
- Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients (PHASE2)
- Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection (NA)
- Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation (PHASE2)
- Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 (PHASE3)
- Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 convalescent plasma treatment CI brief — competitive landscape report
- SARS-CoV-2 convalescent plasma treatment updates RSS · CI watch RSS
- Fundación Santa Fe de Bogota portfolio CI
Frequently asked questions about SARS-CoV-2 convalescent plasma treatment
What is SARS-CoV-2 convalescent plasma treatment?
SARS-CoV-2 convalescent plasma treatment is a Biologic drug developed by Fundación Santa Fe de Bogota.
Who makes SARS-CoV-2 convalescent plasma treatment?
SARS-CoV-2 convalescent plasma treatment is developed by Fundación Santa Fe de Bogota (see full Fundación Santa Fe de Bogota pipeline at /company/fundaci-n-santa-fe-de-bogota).
What development phase is SARS-CoV-2 convalescent plasma treatment in?
SARS-CoV-2 convalescent plasma treatment is in Phase 2.